ArticleJournal of controlled release : official journal of the Controlled Release Society2007
Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 68 citations in OpenAlex.
- Gene Therapy for Cardiovascular Disease: Clinical Perspectives.Yonsei medical journal · 2024Review
- Corneal gene therapy: Structural and mechanistic understanding.The ocular surface · 2023Article
- Recent advances in the development of gene delivery systems.Biomaterials research · 2019Review
- Functional polymers of gene delivery for treatment of myocardial infarct.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Bioreducible polymers for therapeutic gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Bioreducible polycations in nucleic acid delivery: past, present, and future trends.Macromolecular bioscience · 2014Review
- Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Hypoxia-based strategies for angiogenic induction: the dawn of a new era for ischemia therapy and tissue regeneration.Organogenesis · 2013Review
- The effect of environmental pH on polymeric transfection efficiency.Biomaterials · 2012Article
- Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Expert opinion on drug delivery · 2011Review
- Bioreducible polymers for gene delivery.Reactive & functional polymers · 2011Article
- Biocleavable Polycationic Micelles as Highly Efficient Gene Delivery Vectors.Nanoscale research letters · 2010Article
- Reducible poly(amido ethylenimine)-based gene delivery system for improved nucleus trafficking of plasmid DNA.Bioconjugate chemistry · 2010Article
- Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors.Journal of controlled release : official journal of the Controlled Release Society · 2010Article
- Bioreducible hyperbranched poly(amido amine)s for gene delivery.Biomacromolecules · 2009Article
- A family of bioreducible poly(disulfide amine)s for gene delivery.Biomaterials · 2009Article
- Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.Advanced drug delivery reviews · 2009Review
- Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.Journal of controlled release : official journal of the Controlled Release Society · 2008Review
- Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis.Biomaterials · 2008Article
- Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Delivery of the hypoxia-inducible vascular endothelial growth factor (RTP-VEGF) plasmid using a novel reducible disulfide poly(amido ethylenediamine) (SS-PAED) polymer carrier was studied in vitro and in vivo. In vitro transfection of primary rat cardiomyoblasts (H9C2) showed SS-PAED at a weighted ratio of 12:1 (polymer/DNA) mediates 16 fold higher expression of luciferase compared to an optimized bPEI control. FACS analysis revealed up to 57+/-2% GFP positive H9C2s. The efficiency of plasmid delivery to H9C2 using SS-PAED was found to depend upon glutathione (GSH) levels inside the cell. SS-PAED mediated delivery of RTP-VEGF plasmid produced significantly higher levels of VEGF expression (up to 76 fold) under hypoxic conditions compared to normoxic conditions in both H9C2 and rat aortic smooth muscle cells (A7R5). Using SS-PAED, delivery of RTP-VEGF was investigated in a rabbit myocardial infarct model using 100 mug RTP-VEGF. Results showed up to 4 fold increase in VEGF protein expression in the region of the infarct compared to injections of SS-PAED/RTP-Luc. In conclusion, SS-PAED mediated therapeutic delivery improves the efficacy of ischemia-inducible VEGF gene therapy both in vitro and in vivo and therefore, has potential for the promotion of neo-vascular formation and improvement of tissue function in ischemic myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.